Biotech

All Articles

Ascendis' dwarfism medication favorites in period 3, threatens BioMarin

.Ascendis Pharma has actually become a potential hazard to BioMarin's Voxzogo, disclosing phase 3 gr...

Despite ph. 3 overlook, Alkeus observes pathway ahead for eye condition asset

.Though Alkeus Pharmaceuticals' dental eye ailment property stopped working to dramatically lessen g...

Kairos goes social with $6M IPO to money trials of cancer medicine

.With a triad of biotechs reaching the Nasdaq on Friday, it was quick and easy to miss out on a smal...

Vaccine and also Keytruda combo helpful in squamous cell carcinoma

.Immune system gate inhibitors are actually the superheroes of cancer cells therapy. Medications lik...

Cue Biopharma queues up J&ampJ vet as CBO-- Chutes &amp Ladders

.Invite to recently's Chutes &amp Ladders, our summary of significant leadership hirings, firings an...

Regeneron's Opdualag rival shows 57% reaction fee

.Regeneron is back along with long-term consequence for its own LAG-3 inhibitor as well as PD-1 inhi...

AstraZeneca blog posts data on in-house rivals to AbbVie, Pfizer ADCs

.AstraZeneca has discussed a very early take a look at the functionality of its internal antibody-dr...

iTeos- GSK's TIGIT star reveals meaningful remodeling

.After declaring a stage 3 launch based upon favorable midstage end results, iTeos as well as GSK ar...

More collaborative FDA can accelerate unusual illness R&ampD: report

.The FDA should be much more open as well as collective to unleash a rise in approvals of rare disea...

Zenas, MBX, Bicara head to Nasdaq in warm day for biotech IPOs

.It's an uncommonly active Friday for biotech IPOs, along with Zenas BioPharma, MBX and also Bicara ...